DVHGFOTCHealthcare · Biotechnology

Devonian Health Group Inc.

$10.65+0.00%(+$0.00)

TickerSpark Score

49/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DVHGF research report →

52-Week Range98% of range

Low $4.27

Current $10.65

High $10.80

Companygroupedevonian.com

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis.

CEO: Andre Boulet
IPO: 2022
Employees: 6
HQ: Québec, QC, CA

Price Chart

-1.39% · this period

Valuation

Market Cap: $29.62M
P/E: -4.56
P/S: 4.14
P/B: 5.12
EV/EBITDA: -4.41
Div Yield: 0.00%

Profitability

Gross Margin: 41.57%
Op Margin: -42.50%
Net Margin: -90.32%
ROE: -107.78%
ROIC: -51.68%

Growth & Income

Revenue: $17.03M · -4.43%
Net Income: $-4,339,852 · -254.38%
EPS: $-1.76 · -253.01%
Op Income: $-1,027,425
FCF YoY: -116.22%

Performance & Tape

52W High: $10.80
52W Low: $4.27
50D MA: $10.65
200D MA: $7.13
Beta: 1.49
Avg Volume: 1

Get TickerSpark's AI analysis on DVHGF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime